2022 Fiscal Year Final Research Report
Development of novel therapeutics targeting TGF-beta-dependent oral cancer progression
| Project/Area Number |
20K10111
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 57060:Surgical dentistry-related
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | TGF-β / 上皮間葉移行 |
|---|
| Outline of Final Research Achievements |
The number of patients with oral cancer is increasing every year, and the development of effective treatments is urgently needed. Thus, it is important to develop effective treatment methods and search for novel putative targets. Since TGF-β induces epithelial-mesenchymal transition and enhances cell motility and invasiveness in oral squamous cell carcinoma cells, we aimed to develop novel therapeutic agents targeting the molecular mechanisms that regulate TGF-β-induced malignant transformation of oral cancer. In this study, we screened a library of small molecules with known functions and found that isoxsuprine, a low-molecular weight compound can effectively inhibit epithelial-mesenchymal transition. We have also identified factors related to the induction of EMT in oral cancer cells.
|
| Free Research Field |
生化学・がん生物学
|
| Academic Significance and Societal Importance of the Research Achievements |
全世界で口腔がんの患者は年々増加しており有効な治療法の開発が急務である。現在、外科・放射線療法が一定の効果をあげているが、遠隔転移による死亡率が増加しており、有効な治療法の開発が急務である。本研究の成果により口腔がんの上皮間葉移行の新規機構を解明したことの学術的意義は大きく、間葉上皮移行を誘導する活性を有する薬剤として同定した化合物は口腔がん治療への活用が期待されるため、社会的意義も大きい。
|
